4SC AG
4SC AG: Dr Jason Loveridge appointed new CEO of 4SC
4SC AG / Key word(s): Change of Personnel 21.09.2016 14:31 Disclosure of an inside information according to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Dr Jason Loveridge appointed new CEO of 4SC Planegg-Martinsried, Germany, 21 September 2016 - The Supervisory Board of 4SC AG (4SC, FSE Prime Standard: VSC) today appointed Dr Jason Loveridge as new CEO of 4SC. He accepted the appointment and will assume the position effective today. Jason Loveridge graduated in Biochemistry and Microbiology from the University of New South Wales, Australia, and holds a Ph.D. in Biochemistry from the University of Adelaide, Australia. He has more than 20 years of international experience across Europe, Asia and the US in senior management positions in life sciences companies and as an investment professional dealing in both privately held and publicly traded companies. Jason Loveridge also brings substantial transactional experience in the sale and partnering of biotechnology assets to 4SC, which the Supervisory Board believes complements the current team and will help to maximize value for shareholders. --------------------------------------------------------------------------- Information and Explanation of the Issuer to this News: About 4SC 4SC (www.4sc.com) is a biotech company dedicated to the research and development of small-molecule drugs focused on epigenetic mechanisms of action for the treatment of cancers with high unmet medical needs. These drugs are intended to provide innovative treatment options for cancer patients that are more tolerable and efficacious than existing therapies, provide a better quality of life and offer increased life expectancy. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had 50 employees as of 30 June 2016. 4SC has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005. Forward-looking information Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward- looking statements contained herein represent the judgement of 4SC as of the date of this presentation. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. Contact 4SC Corporate Communications & Investor Relations Wolfgang Güssgen, wolfgang.guessgen@4sc.com, +49 89 700763-73 Dr Anna Niedl, anna.niedl@4sc.com, +49 89 700763-66 MC Services Katja Arnold, katja.arnold@mc-services.eu, +49 89 210228-40 The Ruth Group Carol Ruth, cruth@theruthgroup.com, +1 646 536 7004 21.09.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: 4SC AG Am Klopferspitz 19a 82152 Planegg-Martinsried Germany Phone: +49 (0)89 7007 63-0 Fax: +49 (0)89 7007 63-29 E-mail: public@4sc.com Internet: www.4sc.com ISIN: DE000A14KL72 WKN: A14KL7 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden